Indian Pharma Market to Grow by 12-14% Up to 2023
The USD 41 billion Indian pharma industry, the world’s third largest by volume and 13th largest by value, stands to grow by between 12 and 14 percent in the next…
Address: W-199-E, MIDC Khairne, Thane Belapur Road,Navi Mumbai – 400705.,India
Tel: +91-22-4151 5151
Web: http://www.nilsan-nishotech.com/
The Company Started in 1989 as a PROCESS ENGINEERING COMPANY & is today one of the most accomplished and diversified business houses in India having head office in Mumbai , branch office at Hyderabad. At NILSAN Nishotech we have two SBU’S SEPTECH & EPMG. The Group’s success has been driven by the company’s commitment to delivering innovation and excellence. Through the consistent application of this commitment and a century of ethical business conduct, Nilsan Nishotech has earned an unparalleled reputation for trust a,nd reliability.
In 23 years, NILSAN Nishotech is the first company in India to develop the technology to support Pharma, Bio-Pharma , Sugar , Food & Healthcare customers; this spirit of innovation has continued throughout the organization’s history. Today NILSAN Nishotech is delivering exciting engineering innovative solutions across a spectrum of businesses. The company’s pursuit of excellence is equally well established and enduring. NILSAN Nishotech’s management understands that the company’s greatest asset is the trust and faith that customers have reposed in it, and recognizes that the company must continue to earn this trust. This translates to the organization delivering outstanding quality and value in everything it does. We have Overseas association with French Company Novasep (Chromatography Columns) , Austar –China (RO+EDI Skid) , Ziemann –India (Tanks) , DrM – Switzerland (Candle Filtration System) for which we stand one point contact in India.
Sterile Process Piping, Separation Technologies, Pharma Water Technologies
The USD 41 billion Indian pharma industry, the world’s third largest by volume and 13th largest by value, stands to grow by between 12 and 14 percent in the next…
Six Indian pharma and biotech firms have joined the global race to develop a vaccine for COVID-19 with India-developed vaccine candidates moving swiftly toward Phase I and II human trials…
COVID-19 restrictions have severely hampered multinational pharma companies who rely on India for generics and active pharmaceutical ingredients for the last month. With restrictions beginning to ease up, some manufacturing…
A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic pharmaceuticals market. Now accounting for over 90 percent of all prescriptions dispensed in…
The ongoing coronavirus outbreak and the subsequent shutdown of factories in China is having severe repercussions for Indian pharma manufacturers and could lead to global shortages. Shortages and Price…
Below is a selection of the top stories in Indian pharma from recent months, ranging from efforts to counter the coronavirus, to regulatory reform, the spike in USFDA warning letters…
Biocon, the first Indian company to have a biosimilar drug approved in the US, is taking another step forward with a new manufacturing facility and an expansion into the Australia…
The state of Gujarat proudly stands as India’s main pharmaceutical hub, accounting for over 33 percent of the country’s pharmaceutical turnover and 28 percent of its pharmaceutical exports. Given the…
Unlike many of his pharma peers, Vivek Sharma worked in operations and finance for two decades before joining the life sciences industry as head of Piramal Pharma Solutions (PPS) in…
The pharmaceutical industries of China and India, historically focused on their large domestic markets and exports to developed nations, are increasingly forging closer links. With US trade tariffs affecting both…
Aditya Bhattacharji is Healthcare Practice Head at Eurasia Group. In this article, he looks at India’s ambitious healthcare insurance scheme, “Modicare” and delves into some of its critical challenges and associated…
Dilip Shah, the Secretary-General of the Indian Pharmaceutical Alliance advocates for a stronger and more empowered regulator in India if the country is to build public confidence in its pharma output…
See our Cookie Privacy Policy Here
